Ngenla Evropska unija - norveščina - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Dimethyl fumarate Neuraxpharm Evropska unija - norveščina - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Vydura Evropska unija - norveščina - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - migrene lidelser - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Sugammadex Piramal Evropska unija - norveščina - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - neuromuskulær blokkade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Renvela 800 mg Norveška - norveščina - Statens legemiddelverk

renvela 800 mg

orifarm as - sevelamerkarbonat - tablett, filmdrasjert - 800 mg

Elidel 10 mg/ g Norveška - norveščina - Statens legemiddelverk

elidel 10 mg/ g

viatris as - pimecrolimus - krem - 10 mg/ g

Klacid OD 500 mg Norveška - norveščina - Statens legemiddelverk

klacid od 500 mg

viatris as - klaritromycin - depottablett - 500 mg

Visanne 2 mg Norveška - norveščina - Statens legemiddelverk

visanne 2 mg

bayer ab - solna - dienogest - tablett - 2 mg

Mometason Glenmark 1 mg/ g Norveška - norveščina - Statens legemiddelverk

mometason glenmark 1 mg/ g

glenmark arzneimittel gmbh - mometasonfuroat - krem - 1 mg/ g

Veklury Evropska unija - norveščina - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.